Split in the Market Widens as Bank Earnings Hit
New lows topped 500 and more than 60% of stocks are below their 200-day averages, while the mega caps hit another record.
Psst: These Two Biotech Plays Look Like Great Under-the-Radar Deals
Let’s check out two biopharma plays that scream ‘growth at a reasonable price.’
Odd Biotech Action Is Creating Opportunities for Deal Hunters
Let’s see how the best trades are often found by looking past the indexes and digging into what is going on inside a sector.
Large Fund Degrossing Causing Market Divide
This split action has been going on for so long now that everyone is aware of it.
This Is a Good Time to Make a Stock-Picking List
As biotech is getting hit and we’re seeing ETF-driven selling, I smell opportunity for sharp traders.
New Grades, Price Targets for the Top-3 Stocks in Market’s Hottest Sector
Biotech stocks are heating up, as the use of AI technologies accelerates new drug discoveries.
Breakout Buyers Caught in Classic Bull Trap
The problem with traps is that they don’t seem like traps until it’s too late.
Indices Churn On Mix of Good and Bad Action
Financials broke down on the flat yield curve while biotech caught the speculative bid.
2 Names I’m Adding to as Expirations Create Dry Powder
Here are the top two positions worthy of additions as my cash position grows.
After Moderna’s Big News, Here Are Three Biotechs to Watch
I’m following these lesser-known names amid biopharma’s move on Wednesday.